Clinical Trials
21 trialsNCT02220985 2026-06-01
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03959241 2024-04-04
1703/1801
Medical College of Wisconsin
Phase 3 Completed
NCT01858740 2024-03-12
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT01572662 2023-06-29
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00406393 2023-01-04
BMT CTN 0402
Medical College of Wisconsin
Phase 3 Completed
NCT02129582 2021-05-07
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00741455 2020-11-23
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT00004878 2020-07-31
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02487069 2020-03-05
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
Nanfang Hospital, Southern Medical University
Phase NA Completed
NCT01749111 2017-03-03
CICLODECH
Hospital Israelita Albert Einstein
Phase 3 Terminated
NCT00002766 2016-02-22
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT01390402 2016-02-03
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01670084 2015-10-30
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Phase 2 Withdrawn
NCT00402558 2015-05-08
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00002790 2015-03-06
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT01188798 2013-03-21
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00787761 2012-10-01
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Northside Hospital, Inc.
Phase 2 Completed
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00027924 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00002789 2010-03-30
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 3 Completed